Peptide News Digest

Draft Plan for Temporary Sales of Restricted Peptides, an ICOSL Peptide for Kidney Disease, Tirzepatide and COPD Flare-Ups

The Post reports a draft plan to let some restricted peptides be sold for a time, a kidney peptide works in mice, and tirzepatide tracks with fewer COPD flares.

3 stories · Covering regulatory, research

Editor's Note

A quiet Saturday turned on one policy report. The Washington Post said the administration is drafting a way to let compounding pharmacies sell some restricted peptides for a time while the FDA writes formal rules a step that would come after FDA career scientists said in June that the evidence for several such peptides was too weak to support compounding. Nothing has been announced, and the plan could change. In the research journals, a team led from the University of Texas Medical Branch and Rush University showed that a short peptide copied from the immune protein ICOSL protected the kidney filter in mice, and a Taiwanese team's study of a global health-records network linked tirzepatide to fewer COPD flare-ups in people with type 2 diabetes. That study's mortality gap is large enough to suggest bias as well as benefit, since tirzepatide users were followed for less time.

Regulatory

Washington Post: Administration Drafting a Plan to Let Some Restricted Peptides Be Sold Temporarily Through Compounding Pharmacies

The Washington Post reported on October 7, 2026, citing two people familiar with the matter, that the Trump administration is drafting plans to allow temporary sales of some previously restricted peptides while federal health officials write new rules for them; Reuters carried the report, and a summary of the article says the plan would cover seven peptides sold through compounding pharmacies. The plan had not been announced and could change. It follows the FDA advisory committee's July 2026 votes on peptides such as BPC-157; before those votes, FDA career scientists had said the evidence was too weak to support compounding them.

#compounding #fda #bpc-157 #pcac #peptide-regulation
Research

A 19-Amino-Acid Peptide Copied From ICOSL Reduces Protein in the Urine and Protects Kidney Filter Cells in Mice

Researchers from the University of Texas Medical Branch, Rush University Medical Center, and partners in Germany reported in Molecular Biomedicine on October 9, 2026 a 19-amino-acid peptide, hICOSL-19, based on the immune protein ICOSL, that blocks αvβ3 integrin, a receptor whose overactivity damages podocytes, the cells that form the kidney's filter. A longer-lasting PEGylated version reduced protein in the urine, limited kidney damage, and preserved podocyte structure in mouse models of immune-mediated glomerulonephritis and diabetic kidney disease, without signs of T-cell activation or anti-drug antibodies. The results are from mice and cells.

#kidney-disease #integrin #podocytes #preclinical
Research

Tirzepatide Linked to 27% Fewer COPD Flare-Ups Than SGLT2 Inhibitors in People With Type 2 Diabetes, TriNetX Study Finds

Researchers at Chi Mei Medical Center in Taiwan reported in Frontiers in Pharmacology on October 9, 2026 a TriNetX records study of adults with both COPD and type 2 diabetes, matching tirzepatide users one-to-one with users of other diabetes drugs. Compared with 6,080 matched SGLT2 inhibitor users, tirzepatide was associated with fewer COPD flare-ups (hazard ratio 0.73) and lower death rates (0.30), with similar results against DPP-4 inhibitors; against other GLP-1 drugs, flare-up rates were similar. Tirzepatide users were followed for a median of about 233 days versus 365 for the comparison groups, and the size of the mortality gap suggests that differences between the groups, not only the drug, may be at work.

#tirzepatide #copd #type-2-diabetes #real-world-evidence

Related Guides